UBS Group
NAVB

UBS Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

UBS Group’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-149,612
Closed -$13.5K – 10589
2023
Q3 		$13.5K Buy
149,612
+149,362
+59,745% +$13.9K ﹤0.01% 6986
2023
Q2 		$23 Buy
250
+150
+150% +$24 ﹤0.01% 8682
2023
Q1 		$26 Hold
100
– – ﹤0.01% 9401
2022
Q4 		$21 Sell
100
-5
-5% -$1 ﹤0.01% 10550
2022
Q3 		$0 Hold
105
– – ﹤0.01% 11840
2022
Q2 		$0 Hold
105
– – ﹤0.01% 11769
2022
Q1 		$0 Sell
105
-9,266
-99% -$8.49K ﹤0.01% 11620
2021
Q4 		$9K Buy
9,371
+4,073
+77% +$5.73K ﹤0.01% 8998
2021
Q3 		$9K Sell
5,298
-1,512
-22% -$2.54K ﹤0.01% 8171
2021
Q2 		$12K Buy
6,810
+4,124
+154% +$7.29K ﹤0.01% 7948
2021
Q1 		$5K Buy
2,686
+1,870
+229% +$4.38K ﹤0.01% 8394
2020
Q4 		$2K Sell
816
-969
-54% -$2.28K ﹤0.01% 8181
2020
Q3 		$5K Buy
1,785
+1,680
+1,600% +$6.03K ﹤0.01% 7371
2020
Q2 		$0 Hold
105
– – ﹤0.01% 8765
2020
Q1 		$0 Buy
105
+100
+2,000% +$110 ﹤0.01% 8881
2019
Q4 		$0 Sell
5
-4,676
-100% -$4.04K ﹤0.01% 8800
2019
Q3 		$3K Buy
4,681
+4,576
+4,358% +$2.81K ﹤0.01% 7705
2019
Q2 		$0 Sell
105
-6,169
-98% -$12K ﹤0.01% 8475
2019
Q1 		$17K Buy
6,274
+2,136
+52% +$6.3K ﹤0.01% 6464
2018
Q4 		$9K Buy
4,138
+214
+5% +$882 ﹤0.01% 7320
2018
Q3 		$18K Buy
3,924
+1,062
+37% +$4.02K ﹤0.01% 6879
2018
Q2 		$13K Buy
2,862
+501
+21% +$2.62K ﹤0.01% 7014
2018
Q1 		$17K Sell
2,361
-4,427
-65% -$33.1K ﹤0.01% 6537
2017
Q4 		$48K Sell
6,788
-5,434
-44% -$46K ﹤0.01% 5879
2017
Q3 		$102K Buy
12,222
+11,021
+918% +$93.4K ﹤0.01% 5310
2017
Q2 		$13K Buy
1,201
+651
+118% +$6.44K ﹤0.01% 6620
2017
Q1 		$6K Sell
550
-5,311
-91% -$60.3K ﹤0.01% 6946
2016
Q4 		$75K Buy
5,861
+4,088
+231% +$64.8K ﹤0.01% 5508
2016
Q3 		$32K Sell
1,773
-4,694
-73% -$59.4K ﹤0.01% 5876
2016
Q2 		$69K Sell
6,467
-103,485
-94% -$2.03M ﹤0.01% 5285
2016
Q1 		$2.08M Sell
109,952
-8,294
-7% -$160K ﹤0.01% 2642
2015
Q4 		$3.15M Sell
118,246
-738
-0.6% -$25.6K ﹤0.01% 2379
2015
Q3 		$5.43M Buy
118,984
+23,133
+24% +$872K ﹤0.01% 1850
2015
Q2 		$3.09M Buy
95,851
+16,882
+21% +$490K ﹤0.01% 2558
2015
Q1 		$2.51M Buy
78,969
+49,718
+170% +$1.68M ﹤0.01% 2722
2014
Q4 		$1.11M Buy
+29,251
New +$804K ﹤0.01% 3493

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

UBS Group's NAVB Position: Q4 2023 in Review

UBS Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 149,612 shares — an estimated $13.5K sold.

UBS Group first reported a position in NAVB in Q4 2014 and held it in 36 quarters. The position peaked at $5.43M in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • UBS Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 149,612 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $13.5K.
  • UBS Group first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2014 and held it in 36 quarters.
  • UBS Group's Navidea Biopharmaceuticals Inc. position peaked at $5.43M in Q3 2015.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.